Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accounts Payables (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Accounts Payables for 10 consecutive years, with $31.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 20.51% to $31.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.0 million, a 20.51% decrease, with the full-year FY2025 number at $31.0 million, down 20.51% from a year prior.
  • Accounts Payables was $31.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $40.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $59.8 million in Q2 2024 to a low of $15.6 million in Q3 2021.
  • A 5-year average of $35.0 million and a median of $35.1 million in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 152.5% in 2022, then crashed 42.75% in 2025.
  • Ultragenyx Pharmaceutical's Accounts Payables stood at $17.1 million in 2021, then skyrocketed by 152.5% to $43.3 million in 2022, then dropped by 2.68% to $42.1 million in 2023, then dropped by 7.39% to $39.0 million in 2024, then dropped by 20.51% to $31.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Accounts Payables are $31.0 million (Q4 2025), $40.6 million (Q3 2025), and $34.2 million (Q2 2025).